Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 1c

Note: EPS may not be comparable

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery